Antibodies
18 August 2023
Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study18 August 2023
European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI (teclistamab)17 August 2023
Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers17 August 2023
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-302116 August 2023
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease16 August 2023
Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease16 August 2023
Inmagene’s OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis15 August 2023
IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review15 August 2023
Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma15 August 2023
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept11 August 2023
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors9 August 2023
Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-0017 August 2023
Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab BiosimilarNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports